Cost-Sharing and Productivity
NBER Working Paper No. 18402
---- Acknowledgements ----
Funding for this study was provided by Pfizer Inc. to Truven Health Analytics (formerly Thomson Reuters Healthcare). All opinions expressed are those of the authors. We thank Amanda Farr, MPH for research and programming assistance. The views expressed herein are those of the authors and do not necessarily reflect the views of the National Bureau of Economic Research.
---- Disclosure of Financial Relationships for Teresa B. Gibson ----
Teresa B. Gibson is a salaried employee of Truven Health Analytics, a health care consulting firm that performs contract research. In this capacity she has performed studies funded by BMS, Merck, Pfizer and the National Pharmaceutical Council.
---- Disclosure of Financial Relationships for Michael E. Chernew ----
Consultant: Abbott, AonHewitt, AstraZeneca, Aventis Pharmaceuticals, Blue Shield of California, Bristol-Myers Squibb, Center for Medicare and Medicaid Services [CMS], Genentech, GlaxoSmithKline, Health Alliance Plan, Highmark BlueCross BlueShield, Merck and Co., National Business Coalition on Health, National Pharmaceutical Council, Neocure Group LLC, Pennsylvania State Trooper’s Association, Pfizer Inc., POZEN, Inc., Precision Health Economics LLC, Thomson Reuters, TriZetto, zanzors
Speaker’s Bureau: Merck and Co., Pfizer Inc.
Research: Abbott, AstraZeneca, Aventis Pharmaceuticals, Eli Lilly, Genentech, GlaxoSmithKline, Merck and Co., Novartis, Pfizer Inc.